Animal study demonstrates improved recovery with delayed NLRP3 inflammasome inhibition in mice, highlighting viable late-stage therapeutic windows for ischemic stroke.
Our results demonstrate that the NLRP3 inflammasome continues to drive neuroinflammation within the subacute stroke phase. NLRP3 inflammasome inhibition leads to a better long-term outcome-even when administered with a delay of 1 day after stroke induction, indicating ongoing inflammation-driven infarct progression. These findings may pave the way for eagerly awaited delayed treatment options in ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Bellut et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: